Raison CL - Search Results

1

Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.

Mehta D, Raison CL, Woolwine BJ, Haroon E, Binder EB, Miller AH, Felger JC. Mehta D, et al. Among authors: raison cl. Brain Behav Immun. 2013 Jul;31:205-15. doi: 10.1016/j.bbi.2013.04.004. Epub 2013 Apr 25. Brain Behav Immun. 2013. PMID: 23624296 Free PMC article. Clinical Trial.

2

The neuroimmunology of stress and depression.

Raison CL, Miller AH. Raison CL, et al. Semin Clin Neuropsychiatry. 2001 Oct;6(4):277-94. doi: 10.1053/scnp.2001.0060277. Semin Clin Neuropsychiatry. 2001. PMID: 11607923

3

Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Capuron L, et al. Among authors: raison cl. Am J Psychiatry. 2003 Jul;160(7):1342-5. doi: 10.1176/appi.ajp.160.7.1342. Am J Psychiatry. 2003. PMID: 12832253 Clinical Trial.

4

Depression in cancer: new developments regarding diagnosis and treatment.

Raison CL, Miller AH. Raison CL, et al. Biol Psychiatry. 2003 Aug 1;54(3):283-94. doi: 10.1016/s0006-3223(03)00413-x. Biol Psychiatry. 2003. PMID: 12893104 Review.

5

When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders.

Raison CL, Miller AH. Raison CL, et al. Am J Psychiatry. 2003 Sep;160(9):1554-65. doi: 10.1176/appi.ajp.160.9.1554. Am J Psychiatry. 2003. PMID: 12944327 Review.

6

Ribavirin may be an important factor in IFN-induced neuropsychiatric effects.

Asnis GM, De La Garza R 2nd, Miller AH, Raison CL. Asnis GM, et al. Among authors: raison cl. J Clin Psychiatry. 2004 Apr;65(4):581; author reply 581-2. doi: 10.4088/jcp.v65n0420b. J Clin Psychiatry. 2004. PMID: 15119925 No abstract available.

7

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.

Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Raison CL, et al. Brain Behav Immun. 2005 Jan;19(1):23-7. doi: 10.1016/j.bbi.2004.05.001. Brain Behav Immun. 2005. PMID: 15581735

8

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Raison CL, et al. J Clin Psychiatry. 2005 Jan;66(1):41-8. doi: 10.4088/jcp.v66n0106. J Clin Psychiatry. 2005. PMID: 15669887 Free PMC article.

9

Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Raison CL, Demetrashvili M, Capuron L, Miller AH. Raison CL, et al. CNS Drugs. 2005;19(2):105-23. doi: 10.2165/00023210-200519020-00002. CNS Drugs. 2005. PMID: 15697325 Free PMC article. Review.

10

Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings.

Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL, Miller AH. Yoshida K, et al. Among authors: raison cl. Neuropsychobiology. 2005;52(2):55-61. doi: 10.1159/000086605. Epub 2005 Jun 29. Neuropsychobiology. 2005. PMID: 15990456

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

146 results

Search Page

Filters